SCHEMBL5690757

SCHEMBL5690757

CCCCCCOc1ccc(CCN)cc1OCCCCCC

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
HTR2A P28223 1/20 0.56
KDM4E B2RXH2 1/20 0.53
ATM Q13315 1/20 0.53
BIRC5 O15392 1/20 0.51
S1PR1 P21453 2/20 0.48
SIGMAR1 Q99720 2/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
S1PR2 O95136 1/20 0.46
S1PR3 Q99500 1/20 0.46
LPAR2 Q9HBW0 1/20 0.46
CNR2 P34972 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
NFKB1 P19838 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11691494 0.98 GLA (0.67) GLASMN1; SMN2HTR2AKDM4EATM
SCHEMBL8000030 0.93 GLA (0.72) GLASMN1; SMN2HTR2AKDM4EATM
SCHEMBL5688791 0.92 KDM4E (0.66) GLASMN1; SMN2HTR2AKDM4EATM
SCHEMBL7989079 0.91 KDM4E (0.68) GLASMN1; SMN2KDM4EATMSIGMAR1
SCHEMBL7317890 0.88 GLA (0.60) GLASMN1; SMN2HTR2AKDM4EATM
SCHEMBL1579905 0.87 CSNK2A1 (0.57) GLASMN1; SMN2BIRC5S1PR1SIGMAR1
SCHEMBL10985234 0.87 CSNK2A1 (0.57) GLASMN1; SMN2BIRC5S1PR1SIGMAR1
SCHEMBL31655441 0.87 CSNK2A1 (0.57) GLASMN1; SMN2BIRC5S1PR1SIGMAR1
SCHEMBL12071540 0.86 KDM4E (0.70) GLASMN1; SMN2HTR2AKDM4EATM
SCHEMBL15800866 0.86 KDM4E (0.70) GLASMN1; SMN2HTR2AKDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1265483-B1 USE OF PHENYLETHYLAMINE DERIVATIVES FOR THE ANITMICROBIAL TREATMENT OF SURFACES CIBA SC HOLDING AG (CH) 2006-03-29 EP disclosed
US-6846492-B2 Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces CIBA SPECIALTY CHEMICALS CORPORATION (US) 2005-01-25 US disclosed
US-20030207884-A1 Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces CIBA SPECIALTY CHEMICALS CORP. 2003-11-06 US disclosed
EP-1265483-A2 USE OF PHENYLETHYLAMINE DERIVATIVES FOR THE ANITMICROBIAL TREATMENT OF SURFACES Ciba SC Holding AG (CH) 2002-12-18 EP disclosed
WO-2001062082-A2 USE OF PHENYLETHYLAMINE DERIVATIVES FOR THE ANITMICROBIAL TREATMENT OF SURFACES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207884-A1 Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces CLTC, TUBA3C, AOC1 GLA 2554/4885SMN1; SMN2 4757/4885HTR2A 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.